|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 9710 Traville Gateway Drive |
Address2 | Number 157 |
City | Rockville |
State | MD |
Zip Code | 20850 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401018877-48
|
||||||||
|
6. House ID# 421930004
|
TYPE OF REPORT | 8. Year | 2013 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Sharon L Cohen |
Date | 10/20/2013 2:42:13 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033
H. J. Res. 59 -- Continuing Appropriations Resolution, 2014
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 Medicare Diabetes Prevention Act of 2013; HR 1257 - Prevent Diabetes in Medicare Act of 2013; HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013; HR 2663/ S 1422 Scoring of Preventive Health Savings; and
S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014, specifically NDPP funding
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sharon |
Cohen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
National Diabetes Prevention Program funding -- S 1284 - Department of Labor, Health and Human Services and Education and Related Agencies Appropriations Act of 2014
Implementation of the Affordable Care and Health Care & Education Affordability Reconciliation Act of 2010 (PL 111-148 and 111-152); diabetes screening
Human growth hormone and rare disease matters
HR 1074/S 539 - National Diabetes Clinical Care Commission Act of 2013
HR 1247/S 945 - Access to Quality Diabetes Education Act of 2013
HR 1915/S 907 - Gestational Diabetes Act of 2013
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sharon |
Cohen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S. Con. Res. 8 -- Concurrent Resolution on the Budget for Fiscal Year 2014
H. Con. Res. 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 2015 through 2033
H. J. Res. 59 -- Continuing Appropriations Resolution, 2014
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
HR 962/S 452 - Medicare Diabetes Prevention Act of 2013; HR 1257 Prevent Diabetes Medicare Act of 2013; HR 1274/S 945 Access to Quality Diabetes Education Act of 2013; HR 1588/ S 740 -- Medicare Drug Savings Act of 2013; HR 2415/ S 1184 - Treat and Reduce Obesity Act of 2013; HR 2663/S 1422 - Scoring of Preventive Health Savings
Medicare diabetes screening and self management
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sharon |
Cohen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
HR 1919 - Safeguarding America's Pharmaceutical Act of 2013
HR 3204 - Drug Quality and Security Act
FDA issues regarding biosimilar products; 340B program matters
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sharon |
Cohen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |